Windtree Therapeutics expects data useful for an end of Phase 2 meeting.
1 report, 0 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Windtree Therapeutics expects data useful for an end of Phase 2 meeting.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Windtree Therapeutics (United States)
company in Philadelphia, United States
Nothing else this week.
Related events
- A company is seeking definitive data for a pre-NDA meeting with the FDA in Raleigh.
- A company submitted study data supporting a PMA submission to the FDA.
- FDA provided guidance for HCW Biologics' IND application.
- Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
Coverage
Newest first; wire copies grouped- Unknown outlet